In a significant stride toward rapid diagnostics, a collaboration between Arizona State University and the Mayo Clinic has fostered the development of a new test for Valley Fever, a fungal lung infection affecting thousands each year, predominantly in the Southwest.
Known scientifically as a Coccidioides infection, Valley Fever leads to symptoms akin to pneumonia and can leave individuals battling illness for an extended period, the details of this affliction were elaborated on the Cleveland Clinic's website and conveyed through FOX 10 Phoenix's coverage, Cleveland Clinic experts highlight the fungus's predominance in soil across the southwest U.S. and parts of Central and South America, with approximately 20,000 cases reported annually. Doug Lake from Arizona State University illuminated the risks associated with this disease, explaining that "the spores can be inhaled, and once they're inhaled, then the fungus transforms in your lung and causes, usually, pneumonia," Lake told adding "They can be sick for months to years."
The new diagnostic tool operates simply; with a single blood drop, the test strip identifies Valley Fever antibodies—if present, a line emerges, delivering results within 10 minutes, a drastic cut from the previous weeks-long waiting period. Emphasizing the urgency of rapid testing, Lake asserted, "They need to know the answer right away. If they can't find the answer right away, they're likely to prescribe the wrong drugs, which would be antibiotics. For Valley fever, that would be the wrong drug," Lake explained to Yahoo News.
In their interviews, both Lake and Thomas Grys of the Mayo Clinic acclaimed the lengthy but valuable journey of research and development, underscoring the essence of funding for research endeavors, "A lot of work from a lot of people," Grys highlighted in the FOX 10 Phoenix report, while denoting the extensive effort required to bring such a test to fruition. As health professionals await approval, aspirations remain for an additional device that could further depict fungal levels within patients, thus refining treatment strategies, Grys mentioned the potential advancement, commenting, "If your levels are half of what they were before, and you're feeling better, well, it's working."
The introduction of this innovative test could significantly expedite critical care for Valley Fever sufferers throughout affected regions, with the earliest possible hospital implementation anticipated for December of this year as per the interview with Grys given to FOX 10 Phoenix.
